Natco Pharma Launches Affordable Generic Semaglutide Injection in India
Natco Pharma launches generic Semaglutide Injection in India on March 21, 2026. Multi-dose vials are priced at ₹1,290/₹1,750 monthly, significantly cheaper than innovator brands. Pen devices launch in April 2026. This aims to increase patient accessibility to GLP-1 therapy.
The launch of a significantly cheaper generic alternative to a high-value drug like Semaglutide has the potential to disrupt the market, increase patient access, and significantly impact Natco Pharma's revenue and market position.
The launch of an affordable generic version of a critical medication like Semaglutide is a positive development for patients and the company, increasing market accessibility and potentially market share.
Natco Pharma Limited has announced the launch of its generic Semaglutide Injection (multi-dose vials) in the Indian market on March 21st, 2026, coinciding with the patent expiry.
The company received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 for manufacturing and marketing generic Semaglutide in multi-dose vials and pen devices. Semaglutide is indicated for the treatment of type 2 diabetes mellitus.
Natco plans to offer the multi-dose vials in strengths of 2mg/1.5ml, 4mg/3ml, and 8mg/3ml under the brand names SEMANATTM and SEMAFULLTM. The MRP for the 2mg/1.5ml and 4mg/3ml vials will be ₹1,290 per month, while the 8mg/3ml vial will be priced at ₹1,750 per month. The pen device, expected to launch in April 2026, will be priced between ₹4,000 and ₹4,500 per month depending on the strength.
Natco is the first company to introduce generic Semaglutide in multi-dose vials in India, offering it at a significantly lower cost – approximately 70% cheaper than the pen device and 90% cheaper than the innovator's brand. This move aims to enhance patient accessibility to GLP-1 therapy and improve long-term compliance. The company is also offering the product to third parties for co-marketing.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.